AZN News and Press, AstraZeneca PLC From 06/02/24

57% of patients treated with IMFINZI were alive at three years in ADRIATIC Phase III trial Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) ​ demonstrated statistically significant and clinically meaningful...

DESTINY-Breast06 results show AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed medicine and ADC to demonstrate clinically meaningful benefit for patients in this setting Additionally, data from DESTINY-Breast03 and DESTINY-Breast07 trials in HER2-positive met...

2024-06-02 06:00:00 ET You're probably familiar with the old adage, "April showers bring May flowers." And you probably know the punchline to the question, "What do May flowers bring?" (The answer: Pilgrims.) But what does June bring? Three Motley Fool contributors think the new month s...

2024-05-31 18:06:40 ET More on AstraZeneca, Fusion Pharmaceuticals, etc. AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market Amgen wins ...

2024-05-31 17:53:13 ET More on Johnson & Johnson Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson: Vital Signs Decent, A Compelling Value Case J&J completes acquisition of cardiac device maker Shockwave Johnson & Jo...

2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...

2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...

2024-05-30 09:14:24 ET Summary Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032...

2024-05-30 07:00:00 ET AstraZeneca (NASDAQ: AZN) , recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of achieving annual revenue exceeding $45 billion by 2023. This targ...

2024-05-29 16:54:54 ET More on Fusion Pharmaceuticals What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Fusion Pharmaceuticals GAAP EPS of -$0.39 misses by $0.06 Ast...